- Home
- URGN vs QD Comparison
URGN vs QD Comparison
Compare URGN & QD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- QD
- Stock Information
- Founded
- URGN 2004
- QD 2014
- Country
- URGN United States
- QD China
- Employees
- URGN N/A
- QD N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- QD Finance: Consumer Services
- Sector
- URGN Health Care
- QD Finance
- Exchange
- URGN Nasdaq
- QD Nasdaq
- Market Cap
- URGN 465.9M
- QD 433.7M
- IPO Year
- URGN 2017
- QD 2017
- Fundamental
- Price
- URGN $10.08
- QD $2.99
- Analyst Decision
- URGN Strong Buy
- QD
- Analyst Count
- URGN 6
- QD 0
- Target Price
- URGN $42.25
- QD N/A
- AVG Volume (30 Days)
- URGN 308.1K
- QD 391.8K
- Earning Date
- URGN 03-13-2025
- QD 03-17-2025
- Dividend Yield
- URGN N/A
- QD N/A
- EPS Growth
- URGN N/A
- QD N/A
- EPS
- URGN N/A
- QD 0.03
- Revenue
- URGN $89,363,000.00
- QD $32,502,011.00
- Revenue This Year
- URGN $12.17
- QD N/A
- Revenue Next Year
- URGN $44.23
- QD N/A
- P/E Ratio
- URGN N/A
- QD $111.50
- Revenue Growth
- URGN 15.64
- QD 4.27
- 52 Week Low
- URGN $9.78
- QD $1.52
- 52 Week High
- URGN $20.70
- QD $3.34
- Technical
- Relative Strength Index (RSI)
- URGN 40.55
- QD 51.41
- Support Level
- URGN $9.86
- QD $2.99
- Resistance Level
- URGN $11.87
- QD $3.34
- Average True Range (ATR)
- URGN 0.50
- QD 0.16
- MACD
- URGN -0.04
- QD 0.01
- Stochastic Oscillator
- URGN 10.95
- QD 43.65
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About QD Qudian Inc. each representing one
Qudian Inc is a consumer-oriented technology company engaged in the operation of online platforms to provide small consumer credit products in the People's Republic of China. It aims to empower financial institutions with its technological capabilities, help them improve marketing and operating efficiency, and enable financial institutions to efficiently connect their diversified financial products with scene traffic across the entire network It derives a majority of its revenue from the People's Republic of China.